A carregar...
Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
Approximately 12–15% of gastric cancers (GCs) are human epidermal growth factor receptor-2 (HER2)-positive (HER2 immunohistochemistry 3 + or 2 + /in situ hybridization + [ERBB2/CEP17 ≥ 2.0]). While the anti-HER2 monoclonal antibody trastuzumab, in combination with chemotherapy, is the standard treat...
Na minha lista:
| Publicado no: | Gastric Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Singapore
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8205906/ https://ncbi.nlm.nih.gov/pubmed/33997928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-021-01196-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|